Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Intimation for Consideration Of Unaudited Financial Results Of The Company For The Quarter And Six Months Ended 30Th September 2019

 SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2019 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 4th November 2019, inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter and six months ended 30th September 2019. Further, kindly note that pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of financial results of the Company on 4th November 2019. This is for your information and record.
21-10-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement Of Investor Complaints For The Quarter Ended September 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- DEBASHIS DEYDesignation :- Company Secretary and Compliance Officer
18-10-2019
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Dear Sir/Madam, Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that the share certificate(s) as per attached details, issued by the Company, have been reported by the registered shareholder(s)/ bona fide purchasers to have been lost/ misplaced/stolen. We request you to kindly take the same on record.
18-10-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Shareholding for the Period Ended September 30, 2019

 Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here
18-10-2019
Bigul

SPARC (129.5): Buy

 Investors with a short-term perspective and contrarian view can buy the stock of Sun Pharma Advanced Research Company (SPARC) at current levels. After
17-10-2019
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Compliance Certificate - Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half Year Ended September 2019

 Pursuant to the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility were duly maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, ( a SEBI registered Category-I Registrar & Share Transfer Agent with Registration Number : INR000004058), as specified under regulation 7(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 during the half year ended 30th September 2019.
16-10-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - SPARC Receives Orphan Drug Designation From The USFDA For Phenobarbital For The Treatment Of Patients With Neonatal Seizures.

 Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation to Phenobarbital for the treatment of patients with neonatal seizures. The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the United States. Orphan Drug Designation will grant seven years of US market exclusivity upon approval of Phenobarbital for the treatment of patients with neonatal seizures. Incentives include waiver of user fee by USFDA and assistance in clinical trial design by USFDA. We request you to kindly take the same on record.
04-10-2019
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Closure of Trading Window

 This is to inform you that, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the Code of Conduct for prevention of Insider Trading ('The CoC'), the Trading Window for trading by Designated Persons of the Company and their immediate relatives shall be closed with effect from Tuesday, 1st October 2019 till 48 hours after the declaration of financial results of the Company for the quarter and half year ended 30th September 2019. The date of Board Meeting for declaration of the financial results for the quarter and half year ended 30th September 2019 will be intimated in due course.
30-09-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Dear Sir/Madam, Further to our letter No. SPARC/Sec/SE/2019-20/028 dated 22nd August 2019 and letter No. SPARC/Sec/SE/2019-20/032 dated 19th September 2019 on the subject, we enclose herewith the Press Release on Update on the above-mentioned subject being released by the Company, which is self-explanatory. You are requested to kindly take the same on your record & disseminate the information through your website.
20-09-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Dear Sir/Madam, Further to our letter No. SPARC/Sec/SE/2019-20/028 dated 22nd August 2019 on the subject, please find enclosed a copy of the presentation by the Company providing update on R&D; Pipeline, which is self-explanatory. You are requested to kindly take the same on your record & disseminate the information through your website.
19-09-2019
Next Page
Close

Let's Open Free Demat Account